ALZN · All filings · Read this filing
What changed 10-Q
Item 5. Other Information
2026-03-11 compared with 2025-12-09 · 3 added, 3 removed, 36 unchanged (14% of the section changed)
2 unchanged sentences
directors and officers adopted , modified, or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during
−Removed: the Company's fiscal quarter ended October 31, 2025 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of
+Added: the Company's fiscal quarter ended January 31, 2026 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of
1934, as amended).
27 unchanged sentences
ALZAMEND NEURO, INC.
−Removed: December 9, 2025
+Added: March 11, 2026
/s/ Stephan Jackman
1 unchanged sentence
Chief Executive Officer (principal executive officer)
−Removed: December 9, 2025
+Added: March 11, 2026
Chief Financial Officer (principal financial and accounting officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.